Barclays PLC Boosts Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL)

Barclays PLC lifted its stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 327.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,688 shares of the company’s stock after acquiring an additional 21,971 shares during the quarter. Barclays PLC owned 0.09% of Candel Therapeutics worth $199,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of CADL. Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics during the second quarter worth $338,000. Rhumbline Advisers purchased a new stake in shares of Candel Therapeutics during the second quarter worth $143,000. Point72 DIFC Ltd purchased a new stake in shares of Candel Therapeutics during the second quarter worth $31,000. Cubist Systematic Strategies LLC purchased a new position in Candel Therapeutics in the second quarter valued at $162,000. Finally, FMR LLC purchased a new position in Candel Therapeutics in the third quarter valued at $46,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 target price (up previously from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Insider Activity at Candel Therapeutics

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $6.05, for a total transaction of $90,750.00. Following the transaction, the insider now owns 944,873 shares of the company’s stock, valued at approximately $5,716,481.65. This trade represents a 1.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider William Garrett Nichols sold 13,935 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $4.56, for a total value of $63,543.60. Following the transaction, the insider now directly owns 100,547 shares in the company, valued at approximately $458,494.32. The trade was a 12.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,327 shares of company stock valued at $337,581 over the last quarter. 41.60% of the stock is owned by insiders.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $8.70 on Tuesday. The firm has a market capitalization of $282.54 million, a PE ratio of -5.03 and a beta of -1.20. The business’s fifty day moving average price is $6.11 and its 200 day moving average price is $6.15. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.18 and a quick ratio of 1.18. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.